ESMO 2019: KEYNOTE-119 Suggests Activity for Pembrolizumab in Some Triple-Negative Breast Cancer

Published by W Butcher on

The phase III KEYNOTE-119 study revealed no significant difference in outcomes with the use of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer. Nevertheless, a pre-planned exploratory analysis suggested that those patients with the highest tumor and immune cell expression of PD-L1 may benefit from this drug. The findings were presented here at the European Society for Medical Oncology (ESMO) Congress 2019, taking place from September 27 to October 1.

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.